Controversies in the management of stage IIIA non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 12, 2008, Pages 1913-1929

  Santos, Edgardo S ^a   Castrellon, Aurelio ^a   Blaya, Marcelo ^b   Raez, Lus E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Adjuvant chemotheraphy; Concurrent chemoradiation; Induction chemotherapy; Lung cancer; N2 disease; Radiation therapy; Stage IIIA

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; VINBLASTINE; VINDESINE;

BLEEDING; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TOXICITY; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE CARE; RADIATION DOSE FRACTIONATION; REVIEW; SURGICAL MORTALITY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; FEMALE; LUNG TUMOR; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 61449558806     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.12.1913     Document Type: Review

References (92)

1. Dillman RO, Herndon J, Seagren SL, Easton WL Jr, Green MR. Improved survival in stage III NSCLC: seven year follow-up of CALGB 8433. J. Natl Cancer Inst. 88(17), 1210-1215 (1996).
2. Le Chevalier T, Arrigada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial of 353 patients. J Natl Cancer Inst. 83 (6), 417-423 (1991).
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 899-909 (1995).
4. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCCI in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006).
5. Zheng Z, Chen T Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356 (8), 800-808 (2007).
6. Tsao MS, Aviel-Ronen S, Ding K et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 25(33), 5240-5247 (2007).
7. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355 (6), 570-580 (2006).
8. Inamura K, Fujiwara T, Hoshida Y et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative, matrix factorization. Oncogene 24(47), 7105-7113 (2005)
9. Raponi M, Zhang Y, Yu J et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 66(15), 7466-7472 (2006).
10. Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8(8), 816-824 (2002).
11. Bhattacharjee A, Richards WG, Staunton J et al., Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98(24), 13790-13795 (2001).
12. Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12(11), 1294-1300 (2006).
13. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small cell lung cancer. N. Engl. J. Med. 356(1), 11-20 (2007).
14. Tsao MS,C. Zhu, K. Ding, D et al. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benent in JBR.10 patients. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 7510).
15. Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J. Clin. Oncol. 18(16), 2981-2989 (2000).
16. Fosella FV, Rivera E, Roth JA. Pre-operative chemotherapy for stage IIIA non-small cell lung cancer. Curr. Opin. Oncol. 8(2), 106-111 (1996).
17. Mountain CF. The international system for staging lung cancer. Semin. Surg. Oncol. 18(2), 106-115 (2000).
18. van Meerbeeck JP, Kramer GW, van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J. Natl Cancer Inst. 99(6), 442-450 (2007).
19. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl.), 243S-265S (2007).
20. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350(4), 351-360 (2004).
21. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005).
22. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 7, 719-727 (2006).
23. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-regafur for adenocarcinoma of the lung. N. Engl. J. Med. 350(17), 1713-1721 (2004).
24. Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small cell lung cancer: implications for the New Intergroup Trial. Clin. Lung Cancer 8 (1), 18-21 (2006).
25. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperativechemotherapy and surgery with surgery alone in respectable stage IIIA non small cell lung cancer. J. Natl Cancer Inst. 86(9), 673-680 (1994).
26. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing pre-operative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N. Engl. J. Med. 330(3), 153-158 (1994).
27. Rosell R, Felip E. Role of multimodality treatment for lung cancer. Semin. Surg. Oncol. 18(2), 143-151 (2000).
28. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann. Thorac. Surg. 53(6), 992-998 (1992).
29. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable, stage IIIA non-small-cell lung cancer. Lung Cancer 21(1), 1-6 (1998).
30. Pisters KM, Ginsberg RJ, Giroux DJ et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J. Thorac. Cardiovasc. Surg. 119(3), 429-439 (2000).
31. Pisters KM, Vallieres E, Bunn P et al. S9900: a Phase III trial of surgery alone or surgery plus pre-operative (preop) paclitaxel/ carboplatin (PC) chemotherapy in early stage non small lung cancer: Preliminary results. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May 2005 (Abstract LBA7012).
32. Pisters KM, Vallteres E, Bunn P et al. S 9900 surgery alone or surgery plus induction paclitaxel carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow up on a Phase II trial. Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007 (Abstract 7520).
33. Depierre A, Milleron B, Moro-Sibilot D et al. Pre-operative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIA non-small-cell lung cancer. J. Clin. Oncol. 20 (1), 247-253 (2002).
34. Nagai K, Tsuchiya R, Mori T et al. Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J. Thorac. Cardiovasc. Surg. 125(2), 254-260 (2003).
35. Gilligan D, Nicolson M, Smith I et al. Pre-operative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 mulcicentre randomized trial and update of systematic review. Lancet 369 (9577), 1929-1937 (2007).
36. Peters GJ, Ruiz van Haperen VW, Bergman AM et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin. Oncol. 23(5 Suppl. 10), 16-24 (1996).
37. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J. Clin. Oncol. 15(2), 744-749 (1997).
38. Van Zandwijk N, Smit EF, Kramer GW et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer. J. Clin. Oncol. 18(14), 2658-2664 (2000).
39. Migliorino MR, De Marinis F, Nelli F et al. A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for stage III non-small cell lung cancer. Lung Cancer 35(3), 319-327 (2002).
40. Santo A, Pedersini R, Pasini F et al. A Phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis. Lung Cancer. 34(Suppl. 4), S15-S20 (2001).
41. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
42. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21(16), 3016-3024 (2003).
43. O'Brien ME, Splinter T, Smit EF et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. An EORTC Phase II study (EORTC 08958). Eur. J. Cancer 39(10), 1416-1422 (2003).
44. Betticher DC, Hsu Schmitz SF, Totsch M et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter Phase II trial. J. Clin. Oncol. 21(9), 1752-1759 (2003).
45. Betticher DC, Hsu Schmitz SF, Tötsch M et al. Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a Phase II study. Br. J. Cancer., 94(8), 1099-1106 (2006).
46. Berghmans T, Paesmans M, Meert AP et al. Survival improvement in resectable non-small cell lung cancer with (neo) adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49(1), 13-23 (2005).
47. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J. Thorac. Oncol. 1(7), 611-621 (2006).
48. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Role of pre-operative chemotherapy for non-small-cell lung cancer: a meta-analysis. Lung Cancer 54(3), 325-329 (2006).
49. Cappuzzo F, Selvaggi G, Gregorc V et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage III A bulky N2 and stage IIIB nonsmall cell lung carcinoma. Cancer 98(1), 128-134 (2003).
50. De Marinis F, Nelli F, Migliorino MR et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study. Cancer 98(8), 1707-1715 (2003).
51. Garrido P, González-Larriba JL, Insa A et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (142) and IIIB (T4NO-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J. Clin. Oncol. 25(30), 4736-4742 (2007).
52. Pisters KM, Mirkovic N, Pass HI, Albain KS. Pre-operative chemotherapy/ radiation therapy for early stage and locally advanced non small cell lung carcinoma. In: Lung Cancer: Principles and Practice (3rd Edition). Pass HI, Carbone DP, Johnson DH, Minna JD, Turrisi AT (Eds). Lippincott Williams & Wilkins, PA, USA 626-649 (2004).
53. Warram J. Pre-operative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study, Cancer 36(3), 914-925 (1975).
54. Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for IIIA (N2) and IIIB non small cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J. Clin. Oncol. 13(8), 1880-1892 (1995).
55. Albain K, Rusch V, Crowley J et al. Long term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIA (N2) and IIIB non small cell lung cancer (NSCLC): 6 year outcomes from Southwest Oncology Group Lung Committee 8805. Proc. Am. Soc. Clin. Oncol. 18, 467a (1999).
56. Albain KS, Swann RS, Rusch VR et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North-American Intergroup 0139 (RTOG 9309). Presented at: 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May 2005 (Abstract 7014).
57. Bonnet R, Schneider CP, Wendt TG et al. Paclitaxel/carboplatin (PC) followed by twice daily chemoradiation (hfRT/PC) versus hfRT/PC followed by PC as induction to surgery in stage III non-small cell lung cancer (NSCLC): randomized Phase III trial of the Lung Cancer Study Group Mitteldeutschland. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 7541).
58. Maas KW, Sharouni SY, Phernambucq EC et al. A-Phase II study of weekly docetaxel/ciplatin and concurrent radiotherapy followed by surgery in patients with stage III non-small cell lung cancer (NSCLC). Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 7586).
59. de Santis S, Donato V, Caruso C et al. Induction (Ind), gemcitabine (G), docetaxel (D) and cisplatin (C) plus concurrent (Con) chemotherapy with thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC). Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 7589).
60. Bueno R, Richards WG, Swanson SJ et al. Nodal stage after induction theraphy for stage IIIA lung cancer determines patient survival. Ann. Thorac. Surg. 70(6), 1826-1831 (2000).
61. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II and IIIA. Chest 117(2), 374-379 (2000).
62. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma. based on the 1997 TNM classification: the Japanese experience. Ann. Thorac. Surg. 71(6), 1759-1764 (2001).
63. Fang D, Zhang D, Huang G, Zhang R, Wang L, Zhang D. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1,905 cases. Ann. Thorac. Surg. 72(4), 1155-1159 (2001).
64. Goya T, Asamura H, Yoshimura H et al. Prognosis of 6644 resected non-small-cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50(2), 227-234 (2005).
65. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311(7010), 899-909 (1995).
66. Scagliotti GV, Fossati R, Torri V et al. Adjuvant Lung Project Italy/European Organization for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J. Natl Cancer Inst. 95(19), 1453-1461 (2003).
67. Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with non-small-cell lung cancer: the surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg. 26(1), 173-182 (2004).
68. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552-3559 (2008).
69. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation atone in stage III non-small-cell lung cancer. N. Engl. J. Med. 323(14), 940-945 (1990).
70. Sadeghi A, Payne D, Rubinstein L, Lad T. Combined modality treatment for resected advanced non-small cell lung cancer: local control and local recurrence. Int. J. Radiat. Oncol. Biol. Phys. 15 (1), 89-97 (1988).
71. Dautzenberg B, Chastang C, Arriagada R et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer 76(5), 779-786 (1995).
72. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N. Engl. J. Med. 343(17), 1217-1222 (2000).
73. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized concrolted trials. Lancet 352(9124), 257-263 (1998).
74. Israel L, Bonadonna G, Sylvester R. Controlled study with adjuvant radiotherapy, chemotherapy, immunotherapy and chemoimmunotherapy in operable squamous carcinoma of the lung. In: Lung Cancer: Progress in Therapeutic Research. Muggia FM Rozenweig M (Eds Raven Press, NY, USA 443-452 (1979).
75. Smolle-Juettner FM, Mayer R, Pinter H et al. 'Adjuvant' external radiation of the mediastinum in radically resected non-small cell lung cancer. Eur. J. Cardiac Surg. 10(11), 947-951 (1996).
76. Astudillo J, Conill C. Role of postoperative radiation therapy in stage IIIA non-small cell lung cancer. Ann. Thorac. Surg. 50(4), 618-623 (1990).
77. Choi NC, Grillo HC, Gardiello M, Scannell JG, Wilkins EW Jr. Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 6(1), 31-35 (1980).
78. Chung CK, Stryker JA, O'Neill M Jr, DeMuth WE Jr. Evaluation of adjuvant postoperative radiotherapy for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 8(11), 1877-1880 (1982).
79. Kirsh MM, Rotman H, Argenta L et al. Carcinoma of the lung: results of treatment over ten years. Ann. Thorac. Surg. 21(5), 371-377 (1976).
80. Sawyer TE, Bonner JA, Gould PM et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 80(8), 1399-1408 (1997).
81. Phlips P, Rocmans P, Vanderhoeft P, Van Houtte P. Postoperative radiotherapy after pneumonectomy: impact of modern treatment facilities. Int. J. Radiat. Oncol. Biol. Phys. 27(3), 525-529 (1993).
82. Roach M, Gandara DR, Yuo HS et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J. Clin. Oncol 13(10), 2606-2612 (1995).
83. Segawa Y, Takigawa N, Kataoka M, Takata I, Fujimoto N, Ueoka H. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 39(1), 91-98 (1997).
84. Felip E, Rosell R, Massuti B et al. The NATCH trial: chemotherapy toxicity and response on the ncoadjuvant arm. J. Thorac. Oncol. 2(8 Suppl. 4), S336 (2007).
85. Nicolson M, Gilligan D, Smith I et al. Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): first results of the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial. J Clin. Oncol. 25(18S), (2007) (Abstract 7518).
86. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery atone in non-small cell lung cancer. J. Thorac. Oncol. 1(7), 611-621 (2006).
87. Cox JD, Pajak TF, Asbell S et al, Interruptions of high-dose radiation therapy decreases long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int. J. Radiat. Oncol. Biol. Phys. 27(3), 493-498 (1993).
88. Jeremic B, Shibamoto Y, Milicic B et al. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/ II) non-small cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. Lung Cancer 40(3), 317-323 (2003).
89. Sandler A, Cray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
90. Zell JA, On SH, Ziogas A, Anton-Culver H. Survival improvements for advanced stage Donbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer 112(1), 136-143 (2008).
91. Lu Y, Lemon W, Liu PY et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 3(12), e467 (2006).
92. De Leyn P, Stroobants S, De Wever W et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer:4 Leuven Lung Cancer Group Study. J. Clin. Oncol. 24(21), 3333-3339 (2006).